gemtuzumab ozogamicin
Sign in to saveAlso known as CMA-676, CDP-771, CMC-676, WAY-CMA-676
pharmaceutical drug
Chemical data
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Antibody drug conjugate
- First approval
- 2000
- Admin. routes
- parenteral
- Indications
- acute myeloid leukemia, leukemia, neoplasm, chronic lymphocytic leukemia
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 151500
- Has use
- medication
Show 4 more facts
- medical condition treated
- acute myeloid leukemia
- World Health Organisation international non-proprietary name
- gemtuzumab ozogamicin
- subject has role
- antibody-drug conjugate
- legal status (medicine)
- boxed warning
Sources (7)
via Wikidata · CC0